c a dbl 100 this year
Target ABBV will be slow and steady higher, despite this ongoing correction.
Pullback from near 55; missed target earnings announcement, but stock higher with phase 3 test for HIV approval.
100 in 2 to 3 years if you got patience.
ABBV HPC partner ENTA upgraded today
Sentiment: Strong Buy